Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study | Citedby Results | Breast Care | Karger Publishers

Skip to Main Content

Skip Nav Destination

Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study

Breast Care (2020) 15 (3): 289–293.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Andrea Botticelli
Agnese Fabbri
Michela Roberto
Daniele Alesini
Alessio Cirillo
Giuliana D’Auria
Eriseld Krasniqi
Eleonora Marrucci
Margherita Muratore
Francesco Pantano
Laura Pizzuti
Ilaria Portarena
Rosalina Rossi
Simone Scagnoli
Paolo Marchetti

Frontiers in Oncology (2022) 12

Letrozole/Ribociclib

Reactions Weekly (2021) 1873 (1): 155.